Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.99 USD
Change Today +0.34 / 5.11%
Volume 68.9K
AKAO On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 4:00 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

achaogen inc (AKAO) Snapshot

Open
$6.60
Previous Close
$6.65
Day High
$7.03
Day Low
$6.59
52 Week High
12/22/14 - $14.19
52 Week Low
05/12/15 - $5.30
Market Cap
126.6M
Average Volume 10 Days
161.0K
EPS TTM
$-1.39
Shares Outstanding
18.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACHAOGEN INC (AKAO)

Related News

No related news articles were found.

achaogen inc (AKAO) Related Businessweek News

No Related Businessweek News Found

achaogen inc (AKAO) Details

Achaogen, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III combating antibiotic resistant enterobacteriaceae trials for the treatment of bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds that target infections caused by acinetobacter baumannii and pseudomonas aeruginosa. The company was incorporated in 2002 and is headquartered in South San Francisco, California.

51 Employees
Last Reported Date: 08/10/15
Founded in 2002

achaogen inc (AKAO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $380.1K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $270.0K
Chief Medical Officer
Total Annual Compensation: $244.4K
Vice President of Finance and Corporate Devel...
Total Annual Compensation: $248.1K
Compensation as of Fiscal Year 2014.

achaogen inc (AKAO) Key Developments

Achaogen, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and First Six Months Ended June 30, 2015

Achaogen, Inc. announced unaudited consolidated earnings results for the second quarter and first six months ended June 30, 2015. For the quarter, the company announced contract revenue of $12,041,000 compared to $5,203,000 for the same period a year ago. Loss from operations was $929,000 compared to $3,338,000 for the same period a year ago. Net loss was $886,000 compared to $3,555,000 for the same period a year ago. Basic and diluted net loss per common share was $0.05 compared to $0.20 for the same period a year ago. The company derived all of its revenue from funding provided under U.S. government contracts in connection with the development of product candidates. The company announced a narrower net loss on higher revenues versus the comparable period in 2014. For the first six months, the company announced contract revenue of $16,921,000 compared to $11,191,000 for the same period a year ago. Loss from operations was $7,159,000 compared to $6,572,000 for the same period a year ago. Net loss was $7,065,000 compared to $7,010,000 for the same period a year ago. Basic and diluted net loss per common share was $0.39 compared to $0.66 for the same period a year ago.

Achaogen Wins $4.5 Million Contract to Develop Treatment for Bacterial Infections

Achaogen won a contract worth up to $4.5 million from the National Institute of Allergy and Infectious Diseases (NIAID) to develop its LpxC inhibitors for the treatment of bacterial infections. The award has a one-year base period worth $1.5 million, with options of up to three more years worth up to an additional $3 million.

Achaogen, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 03:40 PM

Achaogen, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 03:40 PM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States. Speakers: Kenneth J. Hillan, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKAO:US $6.99 USD +0.34

AKAO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKAO.
View Industry Companies
 

Industry Analysis

AKAO

Industry Average

Valuation AKAO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.7x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHAOGEN INC, please visit www.achaogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.